Jury Backs C.R. Bard In AngioDynamics Antitrust Case
Executive Summary
A New York jury found for C.R. Bard in an antitrust case brought by competitor AngioDynamics, who said that the way Bard packaged its catheter tip location systems preloaded into central lines was anti-competitive.
You may also be interested in...
FDA’s Power Morcellation Containment System Guidance Doc Finalized
The US FDA has finalized a guidance document that details performance assessment standards for power morcellation containment systems. The class II devices have been an object of special scrutiny since the agency learned that power morcellation could spread cancerous tissue throughout the body.
EPA Gives Stakeholders Additional 15 Days For EtO Comments
The deadline for comments on the Environmental Protection Agency proposal, which trade groups say could lead to device shortages if implemented, has been moved from 12 June to 27 June.
‘Wait-and-See Time’: Panel Predicts Limited Congressional Action On Devices This Year
An expert panel at the FDLI annual meeting expects the US Congress to want to see more results from recent legislation on devices before it moves ahead with further FDA reform. Though, pandemic-related measures remain a priority.